Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - Proceedings of the …, 2011 - National Acad Sciences
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
[PDF][PDF] Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Sodaa, T Marumotoa, D Friedmann-Morvinskia… - researchgate.net
Results ECs Express Tumor-Specific Marker in Mouse GBM Models. To investigate
angiogenesis in GBMs, we used our recent mouse GBM model (13). As previously reported …
angiogenesis in GBMs, we used our recent mouse GBM model (13). As previously reported …
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto, D Friedmann-Morvinski… - Proceedings of the …, 2011 - cir.nii.ac.jp
抄録< jats: p> Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant
to intensive combination therapies and anti-VEGF therapies. To assess the resistance …
to intensive combination therapies and anti-VEGF therapies. To assess the resistance …
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - … of the National …, 2011 - providence.elsevierpure.com
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
[HTML][HTML] From the Cover: Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - Proceedings of the …, 2011 - ncbi.nlm.nih.gov
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto, D Friedmann-Morvinski… - Proceedings of the …, 2011 - JSTOR
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - Proceedings of the …, 2011 - pubmed.ncbi.nlm.nih.gov
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - … of the National …, 2011 - okayama.elsevierpure.com
抄録 Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to
intensive combination therapies and anti-VEGF therapies. To assess the resistance …
intensive combination therapies and anti-VEGF therapies. To assess the resistance …
[PDF][PDF] Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Sodaa, T Marumotoa, D Friedmann-Morvinskia… - academia.edu
Results ECs Express Tumor-Specific Marker in Mouse GBM Models. To investigate
angiogenesis in GBMs, we used our recent mouse GBM model (13). As previously reported …
angiogenesis in GBMs, we used our recent mouse GBM model (13). As previously reported …
From the Cover: Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells
Y Soda, T Marumoto… - Proceedings of the …, 2011 - ui.adsabs.harvard.edu
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …
combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti …